Announcements
- Mendus presenterar framsteg med NK-cellsprogrammet på Innate Killer Summit
- Mendus to present NK cell program progress at the Innate Killer Summit
- Mendus erhåller avsiktsförklaringar från större ägare och styrelse samt bolagsledning avseende nyttjande av teckningsoptioner av serie TO3
- Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3
- The exercise period for warrants of series TO3 commences today
- Nyttjandeperioden för teckningsoptioner av serie TO3 inleds idag
- Mendus ger verksamhetsuppdatering och presenterar utsikter för vididencel-programmet
- Mendus provides business update and outlook for vididencel program
- Mendus to participate in upcoming industry conferences
- Mendus medverkar på flera branschkonferenser
More ▼
Key statistics
As of last trade, Mendus AB (publ) (1YG:STU) traded at 0.0294, 600.00% above the 52 week low of 0.0042 set on Aug 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.027 |
---|---|
High | 0.03 |
Low | 0.027 |
Bid | 0.0275 |
Offer | 0.0582 |
Previous close | 0.0312 |
Average volume | 0.00 |
---|---|
Shares outstanding | 1.01bn |
Free float | 593.96m |
P/E (TTM) | -- |
Market cap | 513.67m SEK |
EPS (TTM) | -0.2566 SEK |
Data delayed at least 15 minutes, as of Apr 17 2024.
More ▼